ReviewFrontiers in immunology2025
Functional interaction between immune checkpoints and lipid metabolism in the development of arteriosclerosis obliterans.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-target mechanisms and therapeutic potential of Dahuang Zhechong pill in lower extremity peripheral artery disease: a structured narrative review.Frontiers in pharmacology · 2026Review
- LPIN3 emerges as a diagnostic biomarker in Moyamoya disease revealing immune-lipid metabolic crosstalk.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arteriosclerosis obliterans (ASO) is a chronic vascular disease characterized by narrowing or occlusion of the vascular lumen. Its pathogenesis is complex and closely associated with lipid metabolism disorders and chronic inflammation. Although notable progress has been made in the treatment of ASO, it still remains a cause of surgical limb loss globally. In recent years, immune checkpoints have been identified as critical regulators of the immune microenvironment that play a significant role in ASO. Furthermore, immune checkpoints can affect lipid metabolism by regulating the metabolic pathways of immune cells, thereby indirectly modulating lipid metabolic processes, such as lipid absorption, transport, and degradation, which are crucial in the development and progression of atherosclerosis. Here, we summarized and discussed progress in studies related to lipid metabolism and immune checkpoints during ASO, and highlighted how immune checkpoints regulate lipid metabolism to affect ASO. Further exploration of the interactions between lipid metabolism regulators and immune checkpoints may uncover novel potential therapeutic targets for ASO management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.